Sexually transmitted infections (STIs) constitute a huge health and economic burden for developing countries: 75–85% of the estimated 340 million annual new cases of curable STIs occur in these countries, and STIs account for 17% economic losses because of ill health. The importance of STIs has been more widely recognised since the advent of the HIV/AIDS epidemic, and there is good evidence that the control of STIs can reduce HIV transmission. The main interventions which could reduce the incidence and prevalence of STIs include primary prevention (information, education and communication campaigns, condom promotion, use of safe microbicides, and vaccines), screening and case finding among vulnerable groups (for example, pregnant women), STI case management using the syndromic approach, targeted interventions for populations at high risk (for example, sex workers), and in some circumstances (targeted) periodic mass treatment. The challenge is not just to develop new interventions, but to identify barriers to the implementation of existing tools, and to devise strategies for ensuring that effective STI control programmes are implemented in the future.

This paper reviews the extent of the burden of sexually transmitted infections (STIs) in developing countries, with a focus on Africa, and the main strategies that can be used in STI control programmes. We present some of the evidence of the impact and (cost) effectiveness of key STI interventions that have been used in developing countries. We did not intend to perform a systematic review of STI interventions but, rather, decided to include relevant studies and trials that could best illustrate key control strategies in various parts of the world. We first conducted a search of Medline with no date restriction with the key words “sexually transmitted infections” (or diseases) and “interventions” and “developing countries.” We consulted the Cochrane Library for randomised trials on STI and relevant topics (for example, partner notification). We made use of WHO publications on HIV and STI, existing systematic reviews, and our own personal libraries.

**STIs IN DEVELOPING COUNTRIES: THE EXTENT OF THE PROBLEM**

The World Health Organization (WHO) estimates that approximately 340 million new cases of the four main curable STIs (gonorrhoea, chlamydial infection, syphilis, and trichomoniasis) occur every year, 75–85% of them in developing countries (fig 1). STIs impose an enormous burden of morbidity and mortality in developing countries, both directly through their impact on reproductive and child health, and indirectly through their role in facilitating the sexual transmission of HIV infection. The high prevalence of STIs has contributed to the disproportionately high HIV incidence and prevalence in Africa. Conversely, HIV may have contributed to some extent to STI increases, especially of viral agents such as herpes simplex virus (responsible for genital herpes) or human papillomaviruses (some strains being responsible for genital warts, others for cervical, anal, or penile cancers). The greatest impact is on women and infants. The World Bank has estimated that STIs, excluding HIV, are the second commonest cause of healthy life years lost by women in the 15–44 age group in Africa, responsible for some 17% of the total burden of disease.

Systematic and comprehensive STI surveillance is almost non-existent in developing countries. Most epidemiological data have been obtained from prevalence studies, and from sentinel surveillance sites in a few countries. Prevalence surveys suffer from the disparity of population groups surveyed, which have included university students, antenatal clinic attenders, STI clinic attenders, and sex workers. As an example, table 1 summarises the results of a number of prevalence surveys conducted in sub-Saharan Africa. Until the 1990s there were few data from rural communities, but large community based studies conducted in Tanzania and Uganda in recent years have provided a wealth of data on STI incidence and prevalence.

Some reasons for the high prevalence and incidence of STIs in developing countries are shown in box 1.

**CONTROL OF STIs**

According to the WHO and UNAIDS, STI control programmes have three objectives:

- to interrupt the transmission of STIs;
- to prevent the development of diseases, complications, and sequelae; and
- to reduce the transmission of HIV infection.

Health education and condom promotion can modify behaviour, and hence reduce the incidence of STIs. Screening, case finding, improved access to care, and improved case management can prevent complications, and also reduce...
transmission, by shortening the duration of infection. Mass or targeted presumptive periodic treatments attempt to bypass the need for treatment seeking, since STIs are frequently asymptomatic, with the aim to reduce incidence by reducing the pool of infected individuals, in populations with high STI prevalence or incidence.

Primary prevention of STI

Behavioural interventions

Primary prevention aims to modify sexual behaviour in many ways: by encouraging delayed onset of sexual debut, sexual abstinence and mutually faithful sexual relationships, as well as by promoting “safer sex,” which include the reduction of the number of sexual partners, the adoption of “safer” sexual practices such as non-penetrative genital contacts, and finally by promoting the correct use of condoms. This is achieved through information, education and communication (IEC), or peer assisted education programmes. It is particularly important in adolescents, as they often have high rates of STI, but are at the same time more likely to change their behaviour. Interventions targeting individuals often rely on the “rational health belief model,” which is based on the assumption that an individual has the power to make necessary changes. However, in many instances, drugs, poverty, or gender can diminish an individual’s ability to act on his/her intentions. Few rigorous studies have evaluated the impact of behavioural interventions on STIs and HIV, and disappointingly have shown that reported changes in behaviour have not always been reflected in changes in STI incidence or prevalence. However, changes in sexual behaviour evidenced by increased delays in first sex and reduction of the number of partners account for some of the most impressive reductions in HIV prevalence and incidence rates observed in Uganda, although their concomitant impact on STIs has not been measured.

Barrier methods

When used properly and consistently, condoms are one of the most effective methods of protection against HIV and STIs. They can be made readily available on a large scale through free distribution or social marketing, which uses marketing techniques to make these commodities available at affordable prices. In Thailand, the 100% condom programme, which has been promoting 100% use of condoms in commercial sex establishments, overcame many cultural and logistical barriers traditionally associated with condoms. The programme has been linked to increased adoption of safer sex measures, and concomitant decrease in reported STI rates and HIV prevalence among Thai military recruits and a decrease in the number of men attending STI clinics.
Table 1: Prevalence of STIs and RTIs (reproductive tract infections) among women in sub-Saharan Africa in the 1980s and 1990s

<table>
<thead>
<tr>
<th>STI/RTI</th>
<th>High risk populations</th>
<th>Low risk populations</th>
<th>Low risk WHO estimates 1995</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1980s</td>
<td>1990s</td>
<td>1980s</td>
</tr>
<tr>
<td>Chlamydia</td>
<td>14</td>
<td>2-25</td>
<td>8</td>
</tr>
<tr>
<td>Gonorrhoea</td>
<td>24</td>
<td>7-66</td>
<td>16</td>
</tr>
<tr>
<td>Trichomoniasis</td>
<td>17</td>
<td>4-20</td>
<td>11-46</td>
</tr>
<tr>
<td>Syphilis</td>
<td>15</td>
<td>4-32</td>
<td>8</td>
</tr>
<tr>
<td>Candidiasis</td>
<td>NS</td>
<td>NS</td>
<td>33</td>
</tr>
<tr>
<td>Bacterial vaginosis</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
</tbody>
</table>

NS = not studied.

Reproduced from Mayaud" with permission.
Sources 1980s: Wasserheit, Holmes.25
Sources 1990s: Mayaud.26
Includes the following references: high risk groups: three studies among STI clinic attenders in Benin, Malawi, and Tanzania, with numbers ranging from 192 to 560; and three studies among female sex workers in Cote d’Ivoire, Senegal, and the Democratic Republic of Congo (ex-Zaire), with populations ranging from 374 to 1222; low risk groups: five studies among ANC attenders in Cote d’Ivoire, Gabon, Kenya, Mozambique, Tanzania, and the Democratic Republic of Congo (ex-Zaire), with populations ranging from 201 to 1160; and four studies among family planning attenders in Kenya, Tanzania (two), and South Africa.
Many of the studies can be found in Mindel et al.27
Source WHO 1995: Gerbase et al.28

Vaccines
Safe and effective vaccines would potentially considerably simplify the task of STI control programme managers. Unfortunately, hepatitis B is the only potentially sexually transmissible pathogen for which an effective vaccine is currently available,26 although recent report of an efficacious vaccine against human papillomavirus (HPV) is good news.27 The repeated failure to develop protective vaccines against herpes simplex virus has been particularly disappointing, although one large US study has shown protective efficacy against HSV-2 acquisition in the subgroup of women who were initially HSV-1 seronegative.22 A larger trial purposely targeting this population subgroup is under way, although the relevance for developing countries where HSV-1 infection is quasi-universal at young age is uncertain. Even assuming availability of good products, the practicalities of implementing vaccination programmes in the developing world would be formidable, not to mention the acceptability to the target populations and the issue of parental consent, in cases of vaccines that should be provided before entry into sexual life. Moreover, it could be feared that post-immunisation behaviour change, fuelled by a feeling of perceived invulnerability, could paradoxically increase the prevalence of STI for which a vaccine would not be readily available—for example, HIV.

Screening and case finding
Universal serological testing of antenatal clinic attenders for syphilis is recommended by the WHO and is one of the most cost effective health interventions available, although programmes are poorly implemented in many countries.22,23 Simple, point of care tests for syphilis, in a dipstick format, are now commercially available. Although currently more expensive than the rapid plasma regain (RPR) test, they are simpler to perform, and some do not require separation of serum. They have been shown to be highly sensitive and specific.24  Blood donors should be screened for at least hepatitis, syphilis, and HIV to protect recipients, and it may be possible to screen populations such as military recruits and company employees. In all cases, careful attention should be paid to patient confidentiality, counselling, and treatment.

There is an urgent need for simple and cheap diagnostic tests to identify women with asymptomatic or poorly symptomatic cervical infections, in order to avoid sequelae and reduce transmission. These should include women undergoing transcervical procedures (such as insertion of intrauterine devices in family planning, or uterine curetage in abortion clinics), or pregnant women, at risk of transmitting infections to their babies. Other vulnerable or high frequency transmitter groups such as adolescents and sex workers might also benefit from regular screening or case detection.25 A WHO advocated simple sociodemographic risk score which identifies women at greater risk of infection has been tried but it has a poor sensitivity and predictive value.26 The STD Diagnostic Initiative led by the WHO is promoting the development of rapid point of care (POC) tests

ns
and their evaluation in developing country settings. A recent modelling exercise supports the use of POC tests with even moderate performance in terms of sensitivity and specificity (around 50%) in situations where the delay in treatment would result in significant STI transmission.

Promotion of appropriate treatment seeking behaviour: the role of the private sector

Surveys of health seeking behaviour in developing countries indicate that a substantial proportion of people with symptomatic STIs seek treatment in the informal or private sector, from traditional healers, unqualified practitioners, street drug vendors, and from pharmacists and private practitioners, and they will only attend formal public health services after alternative treatments have failed. Self-medication is also popular in many settings. Patients seek care in the private sector for many reasons, including their greater accessibility and convenience, and the more confidential, less judgmental, and less stigmatising nature of the services.

Objective quality of care in the private sector is however difficult to assess because of the range of services offered and the difficulty in accessing practitioners for researchers. A study of private doctors in South Africa showed that fewer than one in 10 patients received adequate doses of antibiotics and in 75% of cases an incorrect drug was prescribed. Likewise, only 11% of pharmacy workers in the Gambia correctly cited the appropriate management of urethral discharge according to national guidelines, and less than 5% provided adequate treatment to “mystery shoppers,” despite stocking some of the required drugs. None of the cases of pelvic inflammatory disease or genital ulcers was adequately treated.

It is possible to improve private sector management of STIs in developing countries. In Jamaica, seminars for public and private physicians and nurses led to an increase in knowledge concerning STI diagnosis. Most practitioners reported an increase in risk reduction counselling. Similar training for pharmacists in Nepal showed an increase of 45% in the correct syndromic treatment of urethritis. This figure dropped to 26% 9 months after the training, indicating the need for continued training and supervision. A study in Lima, Peru, using “mystery shoppers” for the evaluation of an intervention targeting pharmacists, showed improved recognition of male STI syndromes and a significant increase in counselling, but trained pharmacists still failed to recognise syndromes in women and provided ineffective treatment regimens.

Another strategy to increase effective treatment of STIs is to promote pre-packaged therapy for syndromic treatment. A team in Uganda developed the “Clear Seven” kit for the management of men with urethral discharge. The kit contains ciprofloxacin, doxycycline, condoms, partner referral cards and an instruction leaflet, and was socially marketed at clinics, pharmacies, and retail drug shops. The study found that “Clear Seven” users versus controls had significantly higher self reported cure rates (84% v 47%), greater compliance (93% v 87%), and increased condom use during treatment (36% v 18%). Partner referral rates were similar for both groups (39 and 37%).

The private sector should be viewed as a complement to, and not a replacement for, effective and accessible public services. The views of government health authorities and the medical community should be considered when attempting to stimulate effective collaboration between the two sectors.

STI case management

Early diagnosis and effective treatment of STIs is an essential component of STI control programmes. Syndromic case management is an approach based on the recognition of STI associated syndromes (easily identifiable group of symptoms and clinical findings), followed by treatment targeting the common causes of the syndrome. Management is simplified by the use of clinical flowcharts and standardised prescriptions. The approach is particularly suited to settings where diagnostic facilities will be either lacking or unreliable. Moreover, syndromic management leads to immediate treatment, and does not rely on the patient returning for results. It has proved generally to be cost effective, except for the management of women with cervical infections, in whom this simplified approach is neither sensitive nor specific. The advantages and disadvantages of syndromic management are shown in table 2.

Syndromic management guidelines need to be adapted for local use, depending on the prevalent causes of the common syndromes, and the antimicrobial susceptibility of local isolates of Neisseria gonorrhoeae and Haemophilus ducreyi. A laboratory is needed to monitor these parameters, which may change rapidly.

Partner notification and management

Partner notification and management “comprises those public health activities in which sexual partners of individuals with STI are notified, informed of their exposure and offered treatment and support services.” Partner management aims to reduce the prevalence of asymptomatic infection, and to shorten the average period of infectiousness. This in turn is expected to reduce disease transmission. However, while bacterial STIs can be identified and cured, thus breaking the chain of transmission, viral STIs such as HSV-2 and HIV are incurable, and the rationale for partner management is less clear. In the context of syndromic management, it is even more difficult to decide which partners should be treated, and for what. The most practical approach has been to give the same treatment as for the index case, but this will obviously result in over-prescription of antibiotics, especially in the case of partners of women with vaginal discharge, most of whom do not have an STI. In such circumstances, partner notification could potentially lead to serious social and physical consequences for the female index case.

Partners may be reached actively (or “traced”) by health providers, or invited to clinics through provision of a “notification” slip to be remitted by the index case. While strongly recommended by STI experts as an integral component of STI control, little work has been done to assess the effectiveness of partner notification strategies, and their impact on reducing the prevalence and incidence of

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Advantages and disadvantages of syndromic management of STIs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Advantages</strong></td>
<td><strong>Disadvantages</strong></td>
</tr>
<tr>
<td>Problem oriented (responds to patient’s symptoms)</td>
<td>Over-diagnosis and over-treatment with the following consequences:</td>
</tr>
<tr>
<td>High sensitivity for the detection of infections among symptomatic patients, and does not miss mixed infections</td>
<td>Increased drug costs</td>
</tr>
<tr>
<td>Treatment given at first visit</td>
<td>Possible side effects of multiple drugs</td>
</tr>
<tr>
<td>Provides opportunity and time for education and counselling</td>
<td>Changes in vaginal flora</td>
</tr>
<tr>
<td>A voids expensive laboratory tests</td>
<td>Potential for increased drug resistance</td>
</tr>
<tr>
<td>A voids unnecessary return visit for laboratory results</td>
<td>Domestic violence</td>
</tr>
<tr>
<td>Curtails referral to specialist centres</td>
<td>Requires (re)training of staff</td>
</tr>
<tr>
<td>Can be implemented at primary care level</td>
<td>Possible resistance to its introduction from medical establishment</td>
</tr>
<tr>
<td>Cannot be used to detect infections among asymptomatic individuals</td>
<td></td>
</tr>
</tbody>
</table>
STIs in developing countries has never been properly demonstrated.\textsuperscript{42, 43}

**Targeted interventions and periodic presumptive treatment**

Targeted interventions are based on the concept of “core groups”—that is, groups of individuals who have much higher rates of sexual partnerships, and thus may be more likely to acquire and transmit STIs. These core groups and their sexual partners—who form “bridging populations” with the general population—have been shown to be epidemiologically important in driving the STI and HIV epidemics in many parts of the world.\textsuperscript{44–46} Core groups are context specific and when designing interventions it is important to take account of the social and economic forces creating the groups, and to balance disease control measures against the potential for victimisation. Several comprehensive sexual health interventions targeted at core groups have been conducted in developing countries and have demonstrated good impact on the STI and HIV rates among the target populations,\textsuperscript{47–49} and sometimes among their partners.\textsuperscript{50–52}

A successful core group intervention in a South African mining community provided STI treatment services, including periodic (monthly) presumptive treatment with azithromycin, and prevention education to a group of female sex workers living around the mine. The intervention significantly reduced the prevalence of \textit{N. gonorrhoeae} and \textit{C. trachomatis} and genital ulcer disease (GUD) among the high-risk women in the short term. Symptomatic STIs were also reduced among the miners in the intervention area compared to miners living further away.\textsuperscript{53} It is not clear, however, how long such interventions should be sustained, as STIs get quickly re-established in these highly exposed populations.\textsuperscript{54}

Interestingly, a targeted mass treatment programme with azithromycin during a syphilis outbreak in Vancouver, Canada, resulted in a transient decrease of cases for 6 months followed by a rebound effect,\textsuperscript{55} a reminder that, even though feasible, such interventions should not be done routinely and only with caution.

**Mass treatment**

Mass treatment with penicillin was highly successful in the control of non-venereal treponematoses in the 1950s and 1960s.\textsuperscript{56} It has proved less effective in controlling STIs among the more mobile populations of developing countries in the 1990s.

A community randomised trial in the Rakai District of Uganda\textsuperscript{a} assessed the impact on prevalence and incidence of HIV and STI of single dose oral treatment of all adult community members with azithromycin, ciprofloxacin and metronidazole, combined with a single intramuscular penicillin injection for all participants with serological syphilis. Mass treatment was delivered every 10 months at the household level. After two rounds, the prevalence of serological syphilis was significantly lower in the intervention communities (5.6\%) than in the comparison communities (6.8\%). The prevalence of \textit{Trichomonas vaginalis} infection in women was also significantly lower in the intervention communities (9.3\% v 14.4\%). There was, however, no significant difference in the prevalence of other STIs.\textsuperscript{57}

Mathematical modelling suggests, however, that single or multiple rounds of mass treatment combined with continuous availability of syndromic management could be an effective STI and HIV control strategy for many countries.\textsuperscript{58} The comparative advantages of mass treatment and continuous provision of syndromic treatment could be determined through randomised controlled trials with STI services as standard provision in the control group.\textsuperscript{59}

**Impact of community based interventions on STI rates, including HIV, in developing countries**

Three large scale randomised community based STI intervention trials have been conducted in east Africa. They provide some of the best empirical evidence of the impact of various STI intervention strategies in developing countries. A summary of STI incidence or prevalence outcomes in these trials is presented in table 3. Improved STI case management using the syndromic approach offered at primary healthcare facilities in Mwanza, Tanzania, reduced the incidence of HIV in the surrounding populations by nearly 40\%,\textsuperscript{60} as well as reducing the prevalence and incidence of some key STIs.\textsuperscript{61} However, this effect was not seen in Rakai, Uganda, where periodic mass treatment did not impact on HIV acquisition rates, and only moderately on some of the STI rates.\textsuperscript{62}

Initially it was thought that perhaps the difference in findings from these two trials was related in some way to differences in intervention type.\textsuperscript{63} However, recent findings from a three arm community based intervention trial in Masaka, Uganda, found that intensive information, education, and counselling (IEC) with (arm A) or without (arm B) improved STI syndromic management at primary healthcare centres also did not have an effect on HIV seroconversion rates compared to control communities (arm C). However, this trial demonstrated significant reductions in the prevalence and incidence of bacterial STIs in the syndromic treatment arm\textsuperscript{2} (table 3). These contrasting findings led to confusion over the role of STI control for HIV prevention. A detailed re analysis of the data from these three trials confirmed that it was differences in the populations rather than differences in the interventions which led to the different outcomes. The populations differed in sexual behaviour as well as in the prevalence of...
curable STIs, with much higher rates of bacterial infections in Tanzania.\(^6\)

### CHALLENGES IN STI CONTROL

#### Integration of STI prevention and care in reproductive health services and in HIV/AIDS control programmes

There is broad agreement on the need to integrate STI services into reproductive health services. The rationale is that, in some settings, reproductive health programmes are already high profile, and well attended, and could attract additional funds necessary for STI treatment. Moreover, integrated services could reach a wide female population. It has been suggested that at a minimum, STI/HIV risk assessment and prevention services should be provided in all maternal and family planning clinics, and that integrated services should also include syphilis testing and treatment for all pregnant women attending antenatal services.\(^{23}\)

Integration of STI and reproductive health services can miss a key target group—men. This is important as men, because of sexual behaviour and increased mobility, are at higher risk, initially, of contracting STIs; and, once infected, their clinical management is simpler than that of women. Investigators in Bangladesh found that there was a substantial unmet need for STI services for men and that in addition there was a demand for other reproductive and psychosexual services.\(^{62}\)

At the programme level, however, experience from several countries suggests that STI control programmes are probably best integrated within HIV/AIDS programmes to provide greater synergy, since both programmes share a number of control strategies from behavioural interventions to condom programming, and interventions targeted at high risk groups which would not usually be reached by conventional reproductive health services.

#### The changing epidemiology of STI

Additional challenges to STI control include the capacity of pathogens to develop resistance to antimicrobials, and the rapid emergence of some pathogens—for example, herpes simplex virus type 2 (HSV-2), as significant causes of morbidity and important cofactors of HIV transmission.

#### Global antimicrobial resistance of *Neisseria gonorrhoeae*

In most developing countries, a high proportion of isolates of *Neisseria gonorrhoeae* are resistant to common antibiotics such as penicillin, tetracycline or cotrimoxazole (fig 2).\(^{24}\) In order to provide effective treatment and prevent the transmission of resistant isolates, regimens need to be tailored to the prevalence of antimicrobial resistance in the locality. This in turn requires information on patterns of antimicrobial susceptibility. Many industrialised countries have programmes for *N gonorrhoeae* surveillance, but continuous susceptibility data have been lacking in most developing countries. This problem has been approached by the establishment of a global surveillance network—the gonococcal antimicrobial susceptibility programme (GASP), coordinated by WHO.\(^{25}\)

#### Table 3

Summary of HIV and STI results in the three east African STI randomised community trials (differences in risk ratios (Rakai), rate ratios (Masaka) or relative risks (Mwanza) between intervention and comparison groups at follow up)

<table>
<thead>
<tr>
<th></th>
<th>Rakai (mass STI treatment)</th>
<th>Masaka A (IEC alone)</th>
<th>Masaka B (IEC plus syndromic management)</th>
<th>Mwanza (syndromic management)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV serology</td>
<td>↓ 35% at R2 (NS)</td>
<td>↓ 35%</td>
<td>↓ 38%</td>
<td>NA</td>
</tr>
<tr>
<td>Syphilis serology (TPHA+)</td>
<td>↓ at R3</td>
<td>↓ 20% at R3</td>
<td>↓ 20%</td>
<td>NA</td>
</tr>
<tr>
<td>High titre syphilis serology (prevalence)</td>
<td>↓ 36% at R2</td>
<td>↓ 36%</td>
<td>↓ 2%</td>
<td>NA</td>
</tr>
<tr>
<td>HSV-2 serology (incidence)</td>
<td>↓ 35% at R2</td>
<td>↓ 35%</td>
<td>↓ 35% (NS)</td>
<td>NA</td>
</tr>
<tr>
<td>N gonorrhoeae (prevalence)</td>
<td>↓ 72%</td>
<td>↓ 72%</td>
<td>↓ 72%</td>
<td>NA</td>
</tr>
<tr>
<td>C trachomatis (prevalence)</td>
<td>↓ 72%</td>
<td>↓ 72%</td>
<td>↓ 72%</td>
<td>NA</td>
</tr>
<tr>
<td>Symptomatic male urethritis (prevalence)</td>
<td>↓ 72%</td>
<td>↓ 72%</td>
<td>↓ 72%</td>
<td>NA</td>
</tr>
<tr>
<td>T vaginalis in females (prevalence)</td>
<td>↓ 42% at R2</td>
<td>↓ 42%</td>
<td>↓ 42% (borderline)</td>
<td>NA</td>
</tr>
</tbody>
</table>

Keys: ↑ = increase; ↓ = decrease; NA = not available; NS = not significant

R2, R3 = round (of mass treatment) number 2 and number 3.

High titre syphilis defined as TPHA+/RPR titre > 1:8 in Mwanza and Masaka, and TPHA+/TRUST titre > 1:4 in Rakai.

TPHA = Treponema pallidum haemagglutination assay; RPR = rapid plasma reagin; TRUST = toluidine red unheated serum test.

### Figure 2

Antimicrobial resistance of *N gonorrhoeae* in selected countries in the 1990s. (Source: Mayaud and McCormick.\(^7\))

### Figure 3

Proportion of genital herpes, or HSV-2 isolation, over time among patients with genital ulcers in selected sub-Saharan African settings. (Source: Mayaud and McCormick.\(^6\))
The emergence of HSV-2 and the changing pattern of genital ulcer aetiologies

In countries where syphilis and chancroid were endemic, HSV-2 has traditionally been thought to be relatively less important as an aetiologic agent of genital ulcer disease (GUD). This pattern is changing however. Recent studies have found that, while GUD attributable to HSV-2 infection is increasing, that caused by bacteria is decreasing in many areas. HSV-2 now typically represents 40–50% of detectable GUD aetiologies (fig 3). One consequence is that it may be necessary to revise the WHO guidelines for syndromic management of GUD to include anti-HSV treatment. Furthermore, prospective studies have shown that antecedent HSV-2 infection markedly increases the rate of HIV acquisition and/or transmission in serodiscordant couples. Because of the high incidence and prevalence of HSV-2 in many developing countries, effective interventions targeting HSV-2 are urgently needed. Several trials evaluating the feasibility and impact of episodic or suppressive treatment with acyclovir in terms of HIV acquisition and/or transmission are planned.

Mobilising policy, priority setting, capacity building, and multisectoral approaches

The failure to control STIs in the past was not solely the result of antibiotic resistance or any emergent organisms, but simply the result of lack of political will to invest in appropriate control measures, scaling them up, and/or sustaining them. Many governments are reluctant to confront the STI and HIV epidemics and in many instances countries fail to prioritise activities in the face of severe financial and administrative constraints. There are problems in the effective implementation of control programmes because STIs are not just biological and medical problems, but also behavioural, social, political, and economic problems—many facets that have not been adequately addressed in the past. This realisation is slowly translating into more comprehensive approaches to STI control involving several disciplines and will require a multisectoral approach. However, there is an inherent contradiction with this approach, since spreading resources across programmes in many sectors risks stretching already scarce resources with negligible or even negative impact. An alternative approach for policy makers would be to implement a smaller, core set of interventions on a national scale and in this way provide a foundation for expansion of activities.

CONCLUSIONS

The importance of STIs has been more widely recognised since the advent of the HIV/AIDS epidemic, and there is good evidence that their control can reduce HIV transmission. Although many cost effective tools such as condoms, effective drugs, and the syndromic approach to case management are already available for STI control, there is an urgent need for research into more interventions such as vaginal microbiicides, vaccines, and behaviour change.

The essential components of the public health package recommended by the WHO for STI prevention and care are presented in box 2.
These recommendations remain valid several years after such a package was first promoted, as few developing countries widely implemented even the minimum component of comprehensive STI case management. Possible reasons for this are shown in box 3.

The most pressing need now is to discover the reasons behind the failure to act on these recommendations, and to devise strategies for ensuring that effective STI control programmes are implemented in future. More information is also required on the cost effectiveness of the various options available, to enable programmes managers to set evidence based priorities; and, operational research is needed to establish the best way to implement many of them on a large enough scale to help make a difference.

CONTRIBUTORS

Both authors have contributed entirely to the preparation of this manuscript.

Authors’ affiliations

P Mayaud, D Mabey, London School of Hygiene and Tropical Medicine, London, UK

Conflict of interest: none declared.

REFERENCES


ECHO

Slower progression to AIDS in people in stable relationships

A stable partnership seems to slow progression to AIDS or death for patients receiving highly active antiretroviral treatment (HAART), a Swiss cohort study has shown. Exactly how such partnerships might affect outcome is purely speculative but warrants further study, especially of the mechanisms suitable for intervention, say its authors.

The prospective study measured outcomes in patients receiving HAART since before 2002 who had complete baseline data three months before the start of treatment—in all, 3,736 patients, median age 36 years, 29% women, out of 5,350. Patients were asked at six monthly follow ups about stable partnerships—whether they had a stable partner with whom they had had sexual intercourse over the past six months.

Eighty per cent of the cohort (2,985) had a stable partner at some time during the study, and progression to AIDS or death was significantly less with stable partnerships, even after adjustment for other influences (adjusted hazard ratio 0.79 (95% confidence interval 0.63 to 0.98)). Also significant was increase in CD4 count by 50 or 100 above baseline (adjusted hazard ratio 1.11, 1.15, respectively). Patients in the study were more likely to be white Europeans, better educated, and to have had antiretroviral treatment before HAART started; they were less likely to be at the stage of progressing to AIDS than those excluded for missing data. Bias is possible, say the authors.

Social support is known generally to influence mortality but whether partner support affects outcome in HIV infection is not—hence the reason for this study.

Approaches to the control of sexually transmitted infections in developing countries: old problems and modern challenges
P Mayaud and D Mabey

Sex Transm Infect 2004 80: 174-182
doi: 10.1136/sti.2002.004101

Updated information and services can be found at:
http://sti.bmj.com/content/80/3/174

These include:

References
This article cites 47 articles, 12 of which you can access for free at:
http://sti.bmj.com/content/80/3/174#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Drugs: infectious diseases (3182)
HIV / AIDS (2514)
HIV infections (2514)
HIV/AIDS (2514)
Pregnancy (472)
Reproductive medicine (1356)
Condoms (761)
Screening (epidemiology) (984)
Screening (public health) (984)
Sex workers (479)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/